Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set […]
Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]
The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]
Probiota is set with the ambition to connect business and science of the microbiome space, build community, start conversations and inspire innovation, as very well expressed by Nathan Gray from William Reed. Probiota this year […]
Although the April 15, 2020 decision of the U.S. Patent Trial and Appeal Board (PTAB) was to invalidate The University of Chicago’s US microbiome patent, much can be learned and some positive notes echo from […]
Taxonomy is the branch of science that classifies and names organisms. Lactobacillus were first described in 1901 with Lactobacillus delbrueckii, a species indispensable in yogurt, and grew exponentially since the beginning of the 21stcentury thanks to […]
Cancer mutations can be caused by common gut bacteria carried by many people. This was demonstrated by researchers from the Hubrecht Institute (KNAW) and Princess Máxima Center in Utrecht, the Netherlands. By exposing cultured human […]
Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. […]
The Food and Drug Administration (FDA) is informing health care providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation (FMT). The agency is now aware […]
Introduction With every article of the Microbiome Times, one sees the therapeutic microbiome industry edging ever-closer to full commercialisation of their products. Understandably, much of the focus has been on the challenging process of demonstrating […]
Many different chronic diseases have been associated with distinct gut microbiome ‘signatures’, but what has proved challenging to date is the translation of the compositional and functional microbiome differences into novel diagnostics and therapeutics. Moving […]